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DOI 10.1016/j.ccr.2012.04.037SUMMARYMicroRNAs are a class of short 22 nucleotide RNAs predicted to regulate nearly half of all protein coding
genes, including many involved in basal cellular processes and organismal development. Although a global
reduction in miRNAs is commonly observed in various human tumors, complete loss has not been
documented, suggesting an essential function for miRNAs in tumorigenesis. Here we present the finding
that transformed or immortalized Dicer1 null somatic cells can be isolated readily in vitro, maintain the
characteristics of DICER1-expressing controls and remain stably proliferative. Furthermore, Dicer1 null
cells from a sarcoma cell line, though depleted of miRNAs, are competent for tumor formation. Hence,
miRNA levels in cancer may be maintained in vivo by a complex stabilizing selection in the intratumoral
environment.INTRODUCTION
MicroRNAs (miRNAs) are short 22 nucleotide RNAs that
comprise an essential class of regulators predicted to repress
over half of all genes posttranscriptionally (Bartel, 2009; Fried-
man et al., 2009). Consistent with computational predictions of
widespread targeting, they have been implicated experimentally
in a variety of fundamental cellular processes such as cell cycle
(Wang et al., 2008), apoptosis (Chivukula and Mendell, 2008),
and differentiation (Herranz and Cohen, 2010; Stefani and Slack,
2008). Given these broad roles, the relationship between
miRNAs and cancer is understandably complex. At the level of
individual miRNAs, either gains or losses may promote tumor
formation. However, analysis of global miRNA levels in tumorsSignificance
The nearly global decrease in miRNAs observed across a range
may have a valuable therapeutic role. Here we report that som
tumors under certain conditions. However, the failure to detec
site approach, namely a further decrease in these levels, may
a well-characterized sarcoma model, demonstrating that miRN
reduced proliferation and increased cell death. These findin
elements, particularly DICER1, may be a potential therapy for
848 Cancer Cell 21, 848–855, June 12, 2012 ª2012 Elsevier Inc.suggests a surprisingly unidirectional relationship, with multiple
human tumors showing decreased miRNA content (Gaur et al.,
2007; Lu et al., 2005). In some cases, this downregulation may
be directly achieved by decreased expression of DICER1 and
DROSHA, key processing enzymes of miRNA production (Lin
et al., 2010; Martello et al., 2010; Torres et al., 2011) or mutations
in their binding partners (Melo et al., 2009).
Despite these trends toward decreased miRNA expression,
a number of observations suggest that miRNAs may in fact
be important for a variety of tumor types. For instance,
although heterozygous somatic mutations in DICER1 can be
found in tumor genotyping atlases, homozygous loss has not
been reported in these databases (Kumar et al., 2009). Simi-
larly, in rare cases of heterozygous germline DICER1mutations,of human tumors suggests that restoration of miRNA levels
e tumor cells devoid of miRNA activity are viable and form
t human tumors with complete loss suggests that the oppo-
surprisingly also be beneficial. We explore this alternative in
A depletion can indeed inhibit tumor growth rates through
gs suggest that the targeted inhibition of miRNA pathway
the treatment of cancer.
Figure 1. Characterization of KrasG12D;
Trp53–/–;Dicer1–/– Sarcoma Cells
(A) Derivation scheme forDicer1/ sarcoma cells.
Hindlimb injection of Adeno-Cre generates
KrasG12D; Trp53/;Dicer1f/ tumors. Clones iso-
lated following Cre-ER integration and tamoxifen
treatment were genotyped by PCR to identify
Dicer1/ clones.
(B) miRNA expression (copies per cell). Per cell
calculations are based on relative representation
of each miRNA in Dicer1f/ and Dicer1/ small
RNA-seq libraries, normalized to quantitative
northern blot of miR-22 in Dicer1f/ cells (shown in
Figure S1C). miR-21, miR-22, and let-7 family
members are indicated.
(C) Northern analysis for precursor and mature
miRNAs. Glutamine tRNA was used to control for
loading, and a dilution series of Dicer1f/ RNA (1:1
to 1:16) is provided for quantitation.
(D) Luciferase reporter assays for abundant miR-
NAs. The Renilla luciferase reporter contains six
bulged sites for the let-7 family, and two perfect
sites for miR-16 and miR-17. Targeted Renilla
luciferase reporters were normalized to non-
targeted firefly luciferase reporters. Renilla/firefly
luciferase expression was normalized to expres-
sion in the Dicer1f/ sarcoma cell line.
(E) Proliferation assay.
(F) Cell cycle distribution determined by BrdU
labeling.
(G) Apoptosis determined by caspase-3 cleavage
assay.
All error bars represent the SEM (D–G). See also
Figure S1 and Table S1.
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Tumor Formation in the Absence of MicroRNAsthe pleuropulmonary blastomas to which patients are predis-
posed retain an intact DICER1 allele in tumor tissue (Hill
et al., 2009). Somatic point mutations in DICER1 associated
with nonepithelial ovarian cancers are hypomorphic, likely re-
sulting in expression of a full-length protein but in loss of
some specific miRNAs and retention of others, further suggest-
ing a requirement for DICER1 and miRNA expression in tumors
(Heravi-Moussavi et al., 2012). Mouse models of Dicer1 loss in
cancer also suggest an advantage of retaining miRNA regula-
tion. In a mouse model of Dicer1 deletion in the liver, tumors
emerge several months after deletion following a period of
hepatic repopulation by Dicer1-intact ‘‘escapers’’ (Sekine
et al., 2009). In Dicer1-conditional mouse models of either
soft tissue sarcoma or lung adenocarcinoma, haploinsuffi-
ciency of Dicer1 promotes tumor development but homozy-
gous loss of Dicer1 is not observed (Kumar et al., 2009).
Similarly, in both an Em-myc lymphoma model and a retinoblas-
toma model, viable tumors could not be identified following
homozygous Dicer1 deletion (Arrate et al., 2010; Lambertz
et al., 2010). These studies suggest that complete Dicer1 loss
and the subsequent misregulation of gene expression are
highly deleterious to tumor development.Cancer Cell 21, 848–8To better understand how cancer cells
respond to loss of miRNA expression,
we characterized the effects of homo-
zygous deletion of Dicer1-conditional
alleles on the tumorigenicity of an estab-lished line of murine sarcoma cells and on the cellular phenotype
of immortalized murine mesenchymal stem cells (MSCs).
RESULTS
Dicer1 Null Cells Derived from a Mouse Sarcoma
Proliferate Indefinitely In Vitro
Previously, we generated Dicer1-heterozygous tumors by
injection of Adeno-Cre virus into the hindlimbs of KrasLSL-G12D;
Trp53f/f;Dicer1f/f mice. The resultant tumors always retained at
least one conditional Dicer1 allele (Kumar et al., 2009). From
these KrasG12D;Trp53/;Dicer1f/ tumors, we established
sarcoma cell lines and deleted the remaining allele of Dicer1
by transducing the cells with a retroviral construct encoding
MSCV.CreERT2.puro and then activating recombination in vitro
with tamoxifen treatment (Figure 1A). A genotyping time course
indicated efficient homozygous recombination (Figure S1A
available online). After multiple passages, however, genotyping
PCR indicated the outgrowth of heterozygous cells, consistent
with previous findings in both this sarcoma model and an
Em-myc/Dicer1 lymphoma model (Arrate et al., 2010; Kumar
et al., 2009).55, June 12, 2012 ª2012 Elsevier Inc. 849
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Tumor Formation in the Absence of MicroRNAsTo prevent the preferential outgrowth of DICER1-expressing
cells, we isolated monoclonal populations by plating low-density
cultures immediately after a 24 hr treatment with tamoxifen.
The resulting clones appeared at comparable frequencies in
tamoxifen-treated and control cultures, and were also morpho-
logically similar to the parental cell lines. Genotyping PCR
indicated that the majority of isolated clones had deleted the
second allele of Dicer1 (Figure 1A). We also confirmed recom-
bination of the conditional Dicer1 allele at the protein level by
western blot against DICER1 (Figure S1B). Once a KrasG12D;
Trp53/;Dicer1/ clonal line was established, we did not
observe outgrowth of KrasG12D;Trp53/;Dicer1f/ cells, even
after several months of continual passage. Hereafter, we will
refer to the monoclonal homozygous KrasG12D;Trp53/;
Dicer1/ line as Dicer1/ cells and the parental heterozygous
KrasG12D;Trp53/;Dicer1f/ cell line as Dicer1f/ cells. These
results suggest that sarcoma cells survive after homozygous
Dicer1 deletion but have a growth disadvantage relative to cells
retaining Dicer1 expression. To prevent outgrowth of Dicer1f/
sarcoma cells, all subsequent experiments were carried out
with monoclonal Dicer1/ sarcoma cell lines.
To determine whether Dicer1/ clones lacked miRNAs, we
carried out massively parallel sequencing of small RNAs (small
RNA-seq), 15–50 nucleotides in length, from Dicer1f/ and
Dicer1/ sarcoma cells. Both libraries contained comparable
sequencing depths at 9.3 and 9.6 million reads, respectively.
However, due to miRNA loss, sequence complexity was greater
in Dicer1/ cells, which contained 830,000 unique sequences,
relative to 190,000 unique sequences in Dicer1f/ cells. Of
all reads mapping to the genome with 0 or 1 mismatch, 58%
correspond to mature miRNAs in Dicer1f/ cells in comparison
to 0.8% in Dicer1/ cells. Approximately 48% of mature
miRNAs detected in Dicer1f/ cells became undetectable in
Dicer1/ cells, whereas the remainder of miRNAs underwent
a median decrease of 111-fold, confirming the global loss of
mature miRNAs with homozygous Dicer1 loss. By quantitative
northern blot, miR-22 was present at 4,000 copies per cell in
Dicer1f/ sarcoma cells (Figure S1C). Based on the ratio of
miRNA reads in the Dicer1f/ to Dicer1/ small RNA-seq
libraries normalized to the copy number of miR-22 in Dicer1f/
sarcoma cells, miR-22 is present at fewer than 10 copies per
Dicer1/ sarcoma cell. Similarly, based on normalization to
miR-22, other abundant miRNAs such as individual let-7 family
members are also expressed at fewer than ten copies per cell
in Dicer1/ cells, as compared to several thousand in Dicer1f/
cells (Figure 1B). miR-451, a DICER1-independent miRNA pro-
cessed by Ago2 and expressed abundantly in red blood cells,
is not detectable in Dicer1f/ sarcoma cells and is present at
extremely low levels (0.4 copies/cell) in Dicer1/ sarcoma cells
(Cheloufi et al., 2010; Cifuentes et al., 2010). These results indi-
cate near-complete loss of miRNAs upon Dicer1 deletion.
InDicer1f/ cells, the fivemost abundantmiRNAsweremiR-22
(13%), let-7f (7%), let-7a (7%), let-7c (7%), and miR-21 (6%)
(Table S1). CollapsingmiRNAs by seeds, the dominant heptamer
seed sequence corresponds to let-7, accounting for 31.6% of
all miRNA reads. Let-7 dominance has been observed in other
somatic tissues, such as embryonic fibroblasts and neural
precursors (Marson et al., 2008). In addition, we observed
miRNAs associated with tissue-specific expression and func-850 Cancer Cell 21, 848–855, June 12, 2012 ª2012 Elsevier Inc.tion, such as kidney-specific miR-196a and -196b (1.2% com-
bined) (Landgraf et al., 2007) and miR-96 (2.2%), implicated in
progressive hearing loss (Lewis et al., 2009), suggesting broader
regulatory roles for these short RNAs. Reads from the miR-290-
295 cluster, specific to embryonic stem cells, were negligible in
number, distinguishing these cells as somatic. In total, our
results establish let-7 as the dominant seed inDicer1f/ sarcoma
cells and confirm the loss of mature miRNAs following Dicer1
deletion.
As a confirmation of these sequencing results, we performed
northern analysis for let-7g, miR-16, and miR-17, all detected
abundantly in our Dicer1f/ sequencing library. In contrast to
Dicer1f/ cells, Dicer1/ cells showed an absence of mature
miRNAs and concomitant accumulation of precursors (Fig-
ure 1C). Luciferase reporters containing six bulged sites for
let-7g or one perfect site for either miR-16 or miR-17 were also
derepressed 3- to 6-fold, consistent with functional loss (Fig-
ure 1D). To evaluate proliferative differences, we measured
doubling times for each genotype (Figure 1E). Dicer1/ cells
divided more slowly (15 hr) than the Dicer1f/ controls
(12 hr), but without obvious senescence or onset of crisis.
Dicer1/ sarcoma cells exhibited a delay in G1 phase relative
to Dicer1f/ sarcoma cells (Figure 1F). Additionally, the
Dicer1/ sarcoma cells exhibited elevated levels of apoptosis
(Figure 1G).
Dicer1–/– Sarcoma Cells Retain Tumorigenicity In Vivo
Our findings indicate that genetic ablation of Dicer1 is tolerated
in mouse sarcoma cells in vitro. However, in vivo mouse models
and human patient data suggest that homozygous deletion of
Dicer1 is not tolerated in tumors. To test whether proliferative
defects in homozygous Dicer1-deleted tumors, and subsequent
loss through competition in vivo by DICER1-expressing cells,
account for these differences, we carried out tumor formation
assays. Upon subcutaneous injection of 1 3 106 cells into the
flanks of immune-compromised mice, Dicer1/ cells were
indeed tumorigenic, forming tumors at 7/18 sites within
24 days, as compared to 4/8 sites by day 14 for the original
Dicer1f/ strain. To better evaluate the difference in tumor for-
mation kinetics, we repeated this injection experiment with
2.5 3 104 cells. At this lower cell number, Dicer1/ sarcoma
cells began to develop tumors in 45 days, as compared to
22 days for the parental Dicer1f/ sarcoma cell line (Figure 2A).
Pathologic analysis of either Dicer1/ or Dicer1f/ tumors iden-
tified both as high grade sarcomas with pleomorphic nuclei and
abnormal mitoses, consistent with previous reports of KRAS-
driven sarcoma models (Figure 2B) (Kirsch et al., 2007; Kumar
et al., 2007). Sample genotypes could not be readily distin-
guished in a blinded analysis.
We also performed syngeneic injections into immunocompe-
tent C57Bl6/SV129 F1 mice. As before, the rate was slower
than the parental Dicer1f/ line, with the first tumors appearing
7 days after injection of the Dicer1f/ cells and 21 days after
injection of the Dicer1/ cells (Figure S2). Thus, the absence
of DICER1 impairs but does not preclude tumor formation,
even in an immunocompetent background.
Although the sarcoma cells at the time of the injection were
Dicer1/, it is possible that in vivo selection resulted in
outgrowth of contaminating Dicer1f/ cells. Therefore, we
Figure 2. Tumorigenesis of KrasG12D;
Trp53–/–;Dicer1–/– Sarcoma Cells in Trans-
plant Assays
(A) Injection of 2.5 3 104 Dicer1f/ and Dicer1/
sarcoma cells into the flanks of nude mice. Error
bars represent the SEM.
(B) Hematoxylin and eosin section ofDicer1f/ and
Dicer1/ tumors. In (C–F) each lane represents an
independent tumor derived from one injection of
the indicated Dicer1/ sarcoma cell line. Scale
bar represents 100 mm.
(C) PCR genotyping of Dicer1/ tumors. Re-
combined and floxed bands are derived from the
injected tumor cells, whereas wild-type bands
derive from host tissue.
(D) Northern analysis of tumor tissue derived from
sarcoma injections.
(E and F) PCR (E) and northern (F) analysis
following one round of in vitro passage of
secondary tumors. In (C–F), each sample ID
contains a prefix identifying the injected sarcoma
cell clone followed by a suffix identifying the tumor
replicate (e.g., sample 1-3 corresponds to clone 1
and tumor replicate 3).
See also Figure S2.
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Tumor Formation in the Absence of MicroRNAsgenotyped DNA prepared from primary tumor tissue and
confirmed a significant recombined band corresponding to the
injected Dicer1/ cells with an accompanying background
wild-type band contributed by contaminating host tissue (Fig-
ure 2C). Northern analysis of primary tumors revealed accumula-
tion of precursors as well as significant but incomplete depletion
of mature miRNAs (Figure 2D).
To test if the residual miRNAs were a result of contaminating
wild-type tissue, we generated cell lines from these tumors.
PCR genotyping confirmed a depletion of the wild-type tissue
during this process (Figure 2E). By northern blotting, the level
of mature miRNAs was lower than the detection limit of the
blot, and this was again accompanied by enrichment in the
pre-miRNA (Figure 2F). The residual mature miRNA observed
is likely due to host tissue contamination, as evidenced by the
greatest miRNA signal in the tumor sample showing the greatest
wild-type contaminant band by PCR (Figures 2E and 2F). Thus,
injected Dicer1/ cells survived and proliferated in vivo without
recovery of miRNA processing. The earlier in vitro results extend
to an in vivo setting, with sarcoma cells retaining the capacity to
form phenotypically similar tumors, albeit more slowly, in the
absence of DICER1 and miRNAs.Cancer Cell 21, 848–8Mesenchymal Stem Cells Were
Generated as an Alternative Model
of Somatic Dicer1 Deletion
The viability of Dicer1 null sarcoma cells,
which lack TRP53 and express onco-
genic KRAS, may be a function of the
strong oncogenic background required
for rapid in vivo growth or may require
additional genetic alterations that occur
during tumor formation. Therefore, we
tested whether Dicer1 loss could be
tolerated in a defined immortalized cellmodel. Because sarcomas are thought to be mesenchymal in
origin (Clark et al., 2005), we turned to mesenchymal stem
cells (MSCs), a multipotent population of cells that can differen-
tiate into osteoblasts, chondrocytes, adipocytes, or myocytes
(Pittenger et al., 1999).
From a 1-year-old adult Dicer1f/f mouse, we prepared
a primary culture of MSCs that was then immortalized with
a retroviral vector encoding SV40 large T-antigen (Figure 3A).
Individual clones were isolated and analyzed by flow cytometry
to confirm the expression of CD49e and CD106 (Figure 3B, left
panels), surface markers associated with MSCs (Pittenger,
2008), and the absence of CD31, specific to endothelial cells,
and CD45, a marker of hematopoietic stem cells (data not
shown).
To delete Dicer1, we carried out Adeno-Cre-GFP infection
and sorted the infected cells by GFP. This protocol enriched
for Dicer1/ cells, as seen by the predominance of the dele-
tion-specific PCR product 6 days after sorting (Figure S3A).
This signal was accompanied by loss of DICER1 protein (Fig-
ure S3B), as well as a decrease in mature miRNA levels by
qPCR (Figure S3C) and northern blot at day 7 (Figure S3D).
However, as observed for the sarcoma cells, additional passage55, June 12, 2012 ª2012 Elsevier Inc. 851
Figure 3. Derivation and Characterization of Dicer1–/– Mesenchymal Stem Cells
(A) Schematic of MSC preparation. Primary MSC cultures were prepared from the tibia, femur, and pelvic bones of a 1-year-oldDicer1f/fmouse. The primary cells
were then infected with retrovirus encoding SV40 large T-antigen. Monoclonal cultures were then isolated, infected with Adeno-Cre-GFP, sorted by FACS for
GFP-positive cells, and plated at low density to isolate Dicer1-recombined clones.
(B) Cell surfacemarker expression inDicer1f/f (left) andDicer1/ (right) MSCs. Cells were analyzed by flow cytometry with antibodies against CD49e and CD106.
(C) PCR genotyping of clonally isolated Dicer1f/f or Dicer1/MSCs. Clones 6.8 and 6.9 (lanes 3, 4) were derived from parental clone 6 (lane 2), and clones 12.2
and 12.4 (lanes 6, 7) were derived from parental clone 12 (lane 5). PCR genotyping of a Dicer1f/ sarcoma cell line was used as a heterozygous control (lane 1).
(D) Expression of miRNAs in Dicer1f/f and Dicer1/ MSCs. Total RNA was analyzed with a QIAGEN miScript qPCR assay for let-7a, miR-24, -26, and -31. A
representative qPCR experiment is shown. Error bars represent standard deviation.
(E) Luciferase reporter assay for let-7g. The reporter contains six bulged sites. Targeted Renilla luciferase reporters were normalized to nontargeted firefly
luciferase reporters. Renilla/firefly luciferase expression was normalized to expression in the Dicer1f/f MSC line.
(F) Proliferation assay.
(G) Cell cycle distribution determined by BrdU labeling.
(H) Apoptosis determined by caspase-3 cleavage assay.
Error bars represent SEM (E–H). See also Figure S3.
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Tumor Formation in the Absence of MicroRNAsled to a decrease in the deletion-specific PCR band (Figure S3A),
suggesting outgrowth of DICER1-expressing cells.
To prevent competition by cells retaining Dicer1, we repeated
the strategy used for the sarcoma cell lines and isolated clones.
MSCswere infectedwith Adeno-Cre-GFP, sorted for GFP 2 days
later, then plated at low-density after an additional 10 days.
Clones were then isolated, expanded, and PCR genotyped to
confirm recombination (Figure 3C). Of these clones, a majority
(55%) had undergone homozygous deletion of Dicer1, indicating
that immortalized MSCs can readily tolerate loss of Dicer1.
Dicer1/ clones were stably proliferative and remained Dicer1
null after multiple passages (>3 months) as determined by PCR
genotyping (data not shown). All subsequent experiments
were carried out with a monoclonal Dicer1/ MSC line.
Following loss of Dicer1, we observed an 100-fold reduction
of miRNA expression by qPCR analysis of abundant miRNAs
(let-7a, miR-24, -26, and -31) (Figure 3D). We also observed
5-fold derepression of a let-7g luciferase reporter in Dicer1/
cells (Figure 3E). Dicer1/ MSCs exhibited a proliferative lag,
with a doubling time of20 hr relative to14 hr for Dicer1f/f cells
(Figure 3F). Dicer1/ MSCs also exhibited a G1 delay in cell
cycle (Figure 3G) and elevated levels of basal apoptosis (Fig-
ure 3H). Notably, Dicer1/ MSCs remained positive for CD49e
and CD106 (Figure 3B, right panels) and negative for CD31 and
CD45 (data not shown), suggesting a retention of cell identity
in the absence of miRNAs.DISCUSSION
We have carried out homozygous Dicer1 deletion in a Dicer1-
conditional KRAS-activated, Trp53 null sarcoma cell line and
observed resultant loss of miRNA expression by small RNA
sequencing. Relative to Dicer1f/ sarcoma cells, these
miRNA-depleted cells proliferate more slowly, exhibit a cell
cycle delay in G1 phase, and have a higher level of basal
apoptosis. Additionally, we have generated a second in vitro
model of homozygous Dicer1-deletion in murine mesenchymal
stem cells, related in cell type to sarcomas, established from
an adult Dicer1f/f mouse and immortalized in vitro. Similar to
the sarcoma model, MSCs that had undergone homozygous
Dicer1 deletion were readily isolatable but exhibited a reduction
in proliferation, a delay in G1, and an increase in basal
apoptosis.
Strikingly, Dicer1/ sarcoma cells retain the ability, upon
transplant, to form tumors in both immunocompromised and
immunocompetent recipient mice, albeit at slower rates relative
to Dicer1f/- sarcoma cells. We present three compelling lines
of evidence excluding the possibility that these tumors arose
from contaminating Dicer1f/ cells:
(1) Clonal Dicer1/ sarcoma cells were used for the tumor
injection studies to preclude the possibility of Dicer1f/
outgrowth.
(2) Tumors derived from Dicer1/ injections exhibit strong
PCR genotyping bands for (1) recombined Dicer1, and
(2) wild-type Dicer1, derived from host wild-type tissue
associated with the tumors. In contrast, the control tumor
derived from Dicer1f/- cells exhibits a third PCR band,
representing unrecombined floxed Dicer1. This starkdifference in genotype demonstrates that the tumors
that arose from Dicer1/ injections are composed
predominantly of Dicer1/ cells.
(3) In vitro passage of cells derived from Dicer1/ tumors
resulted in depletion of wild-type primary host tissue
and outgrowth of Dicer1/ cells, as determined by PCR
genotyping, and concomitant depletion in miRNA signal
by northern blot. Furthermore, in most tumor samples,
miRNAs were present at levels less than one-sixteenth
of the Dicer1f/ control, likely an overestimate given the
low level of contaminating host-derived cells.
Our results stand in stark contrast to many published reports.
The failure to observeDicer1 null tumors fromDicer1-conditional
in vivo mouse models of cancer have been interpreted to
suggest that DICER1 and miRNAs are essential for tumor forma-
tion and, furthermore, may be required for tumor cell survival.
Contrary to these observations, our results indicate that miRNAs
are not essential for in vitro survival or proliferation. In vivo,
Dicer1 null sarcoma cells, though depleted of miRNAs, are
competent for tumor development. Furthermore, our observa-
tion of tumor growth in an immunocompetent background
demonstrates that miRNAs are not essential for escape from
immune surveillance. In addition, the histological resemblance
of Dicer1/ sarcomas to Dicer1f/ sarcomas, as well as the
retention of cell type-specific cell surface markers in Dicer1/
MSCs, suggest that cellular identity is largely retained despite
loss of miRNAs. Given the high frequency with which Dicer1
null cells can be isolated in both the sarcoma and MSC models,
secondary mutational or other low frequency events beyond
the initial immortalization are likely not necessary to tolerate
DICER1 loss.
Based on the outgrowth of DICER1-expressing cells in vitro
relative to Dicer1/ cells, and the proliferative delay observed
in monoclonal Dicer1/ cells, we conclude that the absence
of Dicer1 null cells in previously characterized mouse models
of cancer is due in part to the preferential outgrowth, in vivo, of
cells expressing DICER1. Notably, tumor genotyping analyses
in published studies have typically been carried out in whole
tumor samples and, as such, do not exclude the possibility
that Dicer1 null cells comprise a subpopulation of the samples.
Furthermore, factors additional to proliferative capacity may
contribute to the preferential outgrowth of DICER1-expressing
cells in vivo. The viability of Dicer1 null transformed cells in our
study indicates that total miRNA loss itself, and resultant genetic
misregulation, is not intrinsically catastrophic, but rather triggers
secondary signals that initiate changes in proliferation or cell
death. Numerous studies have reported that miRNAs mediate
stress responses (Hermeking, 2007; Leung and Sharp, 2010;
Leung et al., 2011a) and loss of DICER1 in embryonic stem cells
results in increased sensitivity to stress (Zheng et al., 2011). Simi-
larly, we have observed that sarcoma cells and MSCs that
lack DICER1 exhibit increased apoptosis. Given the intrinsically
stressful nature of the in vivo tumor environment, the retention of
a miRNA-mediated stress response may provide an additional
growth advantage to tumor cells that retain at least one copy
of Dicer1.
Notably, inactivation of TRP53 is a common feature in both the
sarcoma and MSC models presented here and may facilitate orCancer Cell 21, 848–855, June 12, 2012 ª2012 Elsevier Inc. 853
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Tumor Formation in the Absence of MicroRNAsbe required for viability in the absence of DICER1. This possibility
is consistent with the observation that TRP53 loss allows primary
MEFs to bypass an immediate senescence phenotype induced
by DICER1 loss (Mudhasani et al., 2008). However, TRP53 loss
alone only prolongs proliferative capacity of Dicer1/ MEFs
for a few additional passages (S.N. Jones, personal communica-
tion), suggesting that other events, such as activation of onco-
genes or inactivation of additional tumor suppressor genes, are
required.
In addition to expanding our understanding of DICER1 in
tumorigenesis, the cell lines reported here may complement
existing models such as the hypomorphic DICER1 HCT116
line, a human colorectal cancer line containing homozygous
deletion of exon 5 in the DICER1 gene (Cummins et al., 2006).
The availability of Dicer1/ cancer cells will permit further
characterization of somatic miRNA families through miRNA
transfection and ‘‘add-back’’ cell culture experiments. Finally,
the observations that DICER1 loss leads to a negative selective
pressure in vitro and in vivo suggests that DICER1 activity could
be a therapeutic target.
EXPERIMENTAL PROCEDURES
Animal Work
All animal studies were performed with protocols approved by the NIH and
the Massachusetts Institute of Technology Committee for Animal Care, and
were consistent with the Guide for Care and Use of Laboratory Animals,
National Research Council, 1996 (Institutional Animal Welfare Assurance
No. A-3125-01).
Cell Culture
Sarcoma cells were generated from hindlimb injection of Adeno-Cre into
KrasLSL-G12D;Trp53f/f;Dicer1f/f mice as described previously (Kirsch et al.,
2007). Sarcoma cells infected with MSCV.CreERT2.puro were treated with
250 nM 4-hydroxy tamoxifen for 24 hr to recombine the floxed Dicer1 allele
and plated at clonal density. Primary MSC cultures were prepared from an
adult Dicer1f/f mouse using a previously described protocol (Mukherjee
et al., 2008), immortalized with SV40 large T-antigen, and infected with
Adeno-Cre-GFP to recombine the floxed alleles. Cells were genotyped as
described previously (Calabrese et al., 2007).
Histology
Tumor-bearing animals were sacrificed with CO2 asphyxiation. Tumors were
isolated, fixed in 4% paraformaldehyde, transferred to 70% ethanol, and
embedded in paraffin. Tumors were then sectioned and stained with hematox-
ylin and eosin.
Tumor Injection
A total of 2.53 104, 105, or 106KrasG12D;Trp53/ sarcoma cells ofDicer1f/ or
Dicer1/ genotype were suspended in PBS and subcutaneously injected into
the flanks of Rag2/ or C57Bl6/SV129 F1 mice. Tumors were measured over
time by calipers and volumes were assessed as described previously (Sage
et al., 2000). DNA, RNA, and histological sections were prepared from tumors.
Some tumors were trypsinized and replated for the development of secondary
cell lines as described above.
Small RNA Northerns and Cloning
Small RNA northern blots were performed using 20 mg total RNA on a 15%
denaturing polyacrylamide gel. Following semi-dry transfer to a Hybond-N+
membrane, a DNA oligo probe for glutamine tRNA or LNA probes for let-7,
mir-16, and mir-17 were used for visualization. Small RNA sequencing from
sarcoma lines was carried out as described previously (Leung et al., 2011b).
The sequencing data are available under Gene ExpressionOmnibus accession
GSE34825.854 Cancer Cell 21, 848–855, June 12, 2012 ª2012 Elsevier Inc.SUPPLEMENTAL INFORMATION
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